Adagene Reports First Patient Dosed in Phase 1 Cancer Study
Adagene reported the first patient dosing in a Phase 1 study of muzastotug and INCA33890 against colorectal cancer.
Related stories
Alnylam Shares Decline 28.31% as Law Firm Investigates
The Law Offices of Howard G. Smith says it is continuing a securities fraud investigation after Alnylam Pharmaceuticals shares fell 28.31%.
M impact | EQUITY | Oct 29, 2026, 08:44 PM UTC
Resmed Q1 Profit Rises to $418.413 Million
Resmed reported first-quarter profit of $418.413 million, or $2.92 per share, compared with $348.536 million, or $2.37 per share, a year earlier.
M impact | EQUITY | Oct 29, 2026, 08:44 PM UTC
SanDisk forecasts Q2 revenue of USD 12,200-12,600 million
M impact | EQUITY | Oct 29, 2026, 08:44 PM UTC
Aecon Reports Q3 Profit Beat and Record Backlog
Canada's Aecon reported third-quarter profit above estimates and a record backlog.
M impact | EQUITY | Oct 29, 2026, 08:42 PM UTC
Texas Instruments Directors Report Share Sales
Director and direct shareholder Robert E. Sanchez sold 6,065 Texas Instruments shares on Oct. 27, 2026, in two transactions at weighted average prices of $302.14 and $303.07, for a
H impact | EQUITY | Oct 29, 2026, 08:40 PM UTC
Stryker Q3 2026 Net Profit Falls 12%
Stryker's net profit fell 12% in the third quarter of 2026.
M impact | EQUITY | Oct 29, 2026, 08:39 PM UTC